Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BCRX

BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BCRX
DateTimeSourceHeadlineSymbolCompany
12/17/20243:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
12/17/20243:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
12/17/20243:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
12/17/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
12/17/20243:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
12/16/20243:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
12/13/20243:23PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
12/04/20243:15PMGlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
12/02/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
11/18/20241:00AMGlobeNewswire Inc.BioCryst Launches ORLADEYO® (berotralstat) in IrelandNASDAQ:BCRXBioCryst Pharmaceuticals Inc
11/06/20246:00AMGlobeNewswire Inc.BioCryst to Present at Upcoming Investor ConferencesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
11/05/20244:19PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
11/05/20246:00AMGlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
11/04/20246:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
11/04/20246:00AMGlobeNewswire Inc.BioCryst Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/24/20247:00AMGlobeNewswire Inc.BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/21/20246:00AMGlobeNewswire Inc.BioCryst to Report Third Quarter 2024 Financial Results on November 4NASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/14/20246:00AMGlobeNewswire Inc.BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/10/20246:00AMGlobeNewswire Inc.BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific MeetingNASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/03/20246:00AMGlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/02/20246:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/02/20246:00AMGlobeNewswire Inc.BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton SyndromeNASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/30/20246:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/30/20246:00AMGlobeNewswire Inc.U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National StockpileNASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/17/20246:00AMGlobeNewswire Inc.BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema AttacksNASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/10/202411:09AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/06/20241:00AMGlobeNewswire Inc.BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin SymposiumNASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/05/20246:00AMGlobeNewswire Inc.BioCryst Appoints Dr. Donald Fong Chief Medical OfficerNASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/04/20246:00AMGlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/03/20243:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:BCRX